Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects

Abadi, Asal Jalal; Mirzaei, Sepideh; Mahabady, Mahmood Khaksary; Hashemi, Farid; Zabolian, Amirhossein; Hashemi, Fardin; Raee, Pourya; Aghamiri, Seyed Mahmoud Reza; Ashrafizadeh, Milad; Aref, Amir Reza; Hamblin, Michael R.; Hushmandi, Kiavash; Zarrabi, Ali; Sethi, Gautam

doi:10.1002/ptr.7305

Cited by 130 publications

(76 citation statements)

References 269 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, certain studies focus on optimizing the physical and chemical properties of drugs and increasing the response of patients to anticancer drugs by increasing the local concentration following drug absorption (75,76). In addition, the reduction of adverse reactions and the improvement of the performance status can increase the DI of chemotherapy and improve the curative effect (77,78). As a regulator of CPT-11 in patients with mCRC, Huangqin Decoction can reduce gastrointestinal toxicity and reduce the events of chemotherapy reduction caused by toxicity (79).…”

Section: Discussionmentioning

confidence: 99%

Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)

2022

View full text Add to dashboard Cite

Chemotherapy dose intensity is a momentous parameter of antitumor clinical medication. In certain clinical trials, the actual application dose of the chemotherapeutic drugs is frequently different from the prescribed dose. The chemotherapy dose intensity completed in different trials is also variable, which has an impact on the treatment efficacy, disease prognosis and patient safety. When these agents are tested in the population, chemotherapy reduction and delay or failure to complete the planned cycle constantly occur due to age, performance status, adverse reactions and other reasons, resulting in the modification of the chemotherapy dose intensity. The present review analyzed the correlation between the chemotherapy dose intensity and the incidence of adverse reactions, the treatment efficacy and disease prognosis in clinical trials of metastatic colorectal cancer. Moreover, the clinical applications of chemotherapy dose intensity were discussed. Based on individual differences, the present review analyzed the clinical trials that examined the efficacy of the chemotherapy dose intensity in different patient populations. The conclusions suggested that different populations require a specific dose intensity to reduce treatment toxicity without affecting the curative effect. Contents 1. Introduction 2. Three-drug combination chemotherapy regimens 3. Two-drug combination chemotherapy regimens 4. DI of specific populations 5. Conclusion

show abstract

Section: Discussionmentioning

confidence: 99%

Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)

2022

View full text Add to dashboard Cite

show abstract

“…Curcumin, a phenolic compound, is a low-molecular-weight molecule derived from the rhizome of Curcuma longa L., a member of the Zingiberaceae family [ 32 , 33 , 34 ]. Several pharmacological activities of curcumin have been reviewed, including its antioxidant, antimicrobial, antitumor, and anti-inflammation capabilities [ 32 , 33 ]. Strong evidence indicated a neuroprotective action of curcumin against AD [ 34 , 35 ].…”

Section: Introductionmentioning

confidence: 99%

Surface Modification of Curcumin Microemulsions by Coupling of KLVFF Peptide: A Prototype for Targeted Bifunctional Microemulsions

et al. 2022

View full text Add to dashboard Cite

Curcumin is one of the most promising natural therapeutics for use against Alzheimer’s disease. The major limitations of curcumin are its low oral bioavailability and difficulty in permeating the blood–brain barrier. Therefore, designing a delivery system of curcumin to overcome its limitations must be employed. KLVFF, a peptide known as an amyloid blocker, was used in this study as a targeting moiety to develop a targeted drug delivery system. A prototype of transnasal KLVFF conjugated microemulsions containing curcumin (KLVFF-Cur-ME) for the nose-to-brain delivery was fabricated. The KLVFF-Cur-ME was developed by a titration method. A conjugation of KLVFF was performed through a carbodiimide reaction, and the conjugation efficiency was confirmed by FTIR and DSC technique. KLVFD-Cur-ME was characterized for the drug content, globule size, zeta potential, and pH. A transparent and homogeneous KLVFF-Cur-ME is achieved with a drug content of 80.25% and a globule size of 76.1 ± 2.5 nm. The pH of KLVFF-Cur-ME is 5.33 ± 0.02, indicating non-irritation to nasal tissues. KLVFD-Cur-ME does not show nasal ciliotoxicity. An ex vivo diffusion study revealed that KLVFF-Cur-ME partitions the porcine nasal mucosa through diffusion, following the Higuchi model. This investigation demonstrates the successful synthesis of a bifunctional KLVFF-Cur-ME as a novel prototype to deliver anti-Aβ aggregation via an intranasal administration.

show abstract

“…Chemotherapy in cancer causes organ toxicity such as hepatotoxicity, cardiotoxicity, and renal toxicity as well as many other side effects. When cisplatin is used as chemotherapy, all of these side effects can be reduced by using CUR or its derivatives [8].…”

Section: Introductionmentioning

confidence: 99%

Comparative Study between Curcumin and Nanocurcumin Loaded PLGA on Colon Carcinogenesis Induced Mice

et al. 2022

View full text Add to dashboard Cite

Colorectal cancer is the third most common cancer. Because curcumin (CUR) has anti-inflammatory and anticancer properties, research has been undertaken to indicate that nanocurcumin compounds can be used to treat a variety of cancers. CUR in nanoform has been found to have a stronger effect than conventional CUR. The purpose of this study was to show that CUR-loaded poly lactic-co-glycolic acid nanoparticles (PLGA) (CUR-loaded PLGA) have anti-inflammatory and anticancer effects on colon carcinogenesis in male dimethyl hydrazine (DMH) mice as a comparative study between the nanoform of curcumin and normal curcumin, focusing on the anticancer effect of nanocurcumin. Mice were separated into six groups: No treatment was given to Group I (negative Group-I). Group II was treated with CUR. Group III was treated with CUR-loaded PLGA. Group IV was treated with DMH. Group V received DMH and curcumin. Group VI received DMH and CUR-loaded PLGA. At the conclusion of the trial, the animals were slain (6 weeks). Inflammatory indicators and vascular endothelial growth factor (VEGF) levels all changed significantly in this study, as the following inflammatory markers as TNF showed percent of change compared to the DMH group. Recovery percentage for Groups V and VI, respectively, were 9.18 and 55.31%. In addition, IL1 was 7.45 and 50.37% for Groups V and VI, respectively. The results of IL6 were 4.86 and 25.79% for Groups V and VI, respectively. The vascular endothelial growth factor (VEGF) recovery percent was 16.98 and 45.12% for Groups V and VI, respectively. Following the effect of DMH on colon mucosa shape, the researchers looked at the effect of CUR-loaded PLGA on colon histology. It was shown that CUR-loaded PLGA affects the cell cycle and PCNA expression. We conclude that nanocurcumin is an important anti-inflammatory and cancer-fighting agent.

show abstract

Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects

Abstract: Curcumin is a phytochemical isolated from Curcuma longa with potent tumorsuppressor activity, which has shown significant efficacy in pre-clinical and clinical

Cited by 130 publications

References 269 publications

Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)

Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)

Surface Modification of Curcumin Microemulsions by Coupling of KLVFF Peptide: A Prototype for Targeted Bifunctional Microemulsions

Comparative Study between Curcumin and Nanocurcumin Loaded PLGA on Colon Carcinogenesis Induced Mice

Contact Info

Product

Resources

About